In conclusion, our preclinical data demonstrate that the treatment with simvastatin impairs MCL cell proliferation, triggering ROS-mediated, caspase-independent cell death, associated with the suppression of the activation of the AKT/mTOR signaling pathway. Here, AKT1 is linked to mantle cell lymphoma.